COVID-19 vaccine recommendations could be changing, according to the U.S. Food and Drug Administration. FDA leaders said on May 20 that clinical trials will be required to approve annual COVID-19 ...

Shares of Moderna on Wednesday surged to their highest in more than a year after the pharmaceutical company said it reached a deal to resolve a dispute related to its COVID vaccine. Moderna MRNA said ...

Moderna MRNA-1.55%decrease; red down pointing triangle will pay $950 million to settle patent litigation by Arbutus Biopharma and Genevant Sciences GmbH. The vaccine maker said Tuesday that, as part ...

Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a long-running legal fight over the technology ...

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. Moderna will pay $950 million ...

The Trump administration weighs candidates to lead the CDC, with two physicians with contrasting views on vaccines ...

A federal judge blocked parts of HHS's vaccine policy changes, siding with medical groups against Robert F. Kennedy Jr.'s ...

The Florida Legislature passed a bill allowing high school booster clubs to directly compensate coaches. Supporters argue the measure will help Florida schools compete with neighboring states that ...

Immatics N.V. remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a robust cell therapy pipeline. IMTX’s valuation reflects high expectations, with the PRAME franchise and ...

The United States is expected to deploy a third aircraft carrier to the Middle East, Fox News reports. USS George H.W. Bush completed its pre-deployment training on Thursday, according to the US Navy.

Teenage Mutant Ninja Turtles is the latest Universes Beyond set for Magic: The Gathering, and it's out this week. If you’re already sold on meeting up with cardboard versions of the Heroes in a Half ...

Moderna shares tumbled last week after the Food and Drug Administration refused to review an application for its new seasonal flu vaccine. Now the FDA seems to have changed its tune.